Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab for early polymyalgia rheumatica
2024-511296-15-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of sarilumab in polymyalgia rheumatica (PMR) (3 arms), sponsored by Sanofi. Primary endpoint: Sustained remission at Week 52 in early relapsing PMR (sarilumab 200 mg q2w + prednisone taper). Planned start Jul 2026; status: authorised.
02
Drugs
sarilumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2024-511296-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511296-15-00.